Different genomic mutations signatures are associated to specific PD-L1/TMB states on lung cancer with potential value for patients screening for immunotherapy
Clin Chim Acta. 2015 Dec 7;451(Pt A):97-102. doi: 10.1016/j.cca.2015.01.003. Epub 2015 Jan 10.